Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3

NCT05492682 is registered in ClinicalTrials.gov with Valo Therapeutics Oy as lead sponsor.

NCT NCT05492682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05492682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3
Lead sponsor
Valo Therapeutics Oy
Phase
Phase 1
Overall status
Recruiting
Start date
February 2, 2023
Completion date
May 31, 2027
Enrollment
15 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, melanoma (skin), myxoid liposarcoma, non-small cell lung cancer, osteosarcoma, sarcoma, synovial sarcoma, triple-negative breast cancer